The Extended Salford Lung Study (“Ex-SLS”) Data Access Project
Research type
Research Study
Full title
The Extended Salford Lung Study (“Ex-SLS“) Data Access Project
IRAS ID
217283
Contact name
Ashley Woodcock
Contact email
Sponsor organisation
GlaxoSmithKline Ltd
Clinicaltrials.gov Identifier
CPMS ID PRIM , 33279
Duration of Study in the UK
10 years, 9 months, 17 days
Research summary
COPD and asthma are prevalent chronic respiratory diseases with significant global impact. Gaining a better understanding of the causes, treatment and consequences of COPD and asthma is vital to reducing the associated public health burden. The Salford Lung Studies (SLS) subjects represent a group of patients whose disease is extremely well-characterised over a short time period. Broadened access to these patients’ data would present a rare opportunity to improve scientific and clinical understanding of COPD/asthma disease risk and progression, treatment pattern evolution, medication effectiveness and long term safety. Furthermore, the capture, via a patient questionnaire, of historical demographic, COPD/asthma risk factor and clinical information would improve our understanding of the natural history of these diseases. We are therefore seeking SLS patients’ consent to collect and study these additional data. The SLS studies were conducted in Salford as a collaboration between North West eHealth (NWeH), part of Salford Royal Foundation Trust, the University of Manchester, GPs and community pharmacies in Salford, Stockport, Trafford & South Manchester and are sponsored by GlaxoSmithKline Research and Development Ltd (GSK). \n
REC name
North West - Greater Manchester East Research Ethics Committee
REC reference
17/NW/0122
Date of REC Opinion
20 Apr 2017
REC opinion
Further Information Favourable Opinion